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AbstrACt
background In vivo targeting of human papillomavirus 
(HPV) derived antigens to dendritic cells might constitute 
an efficient immunotherapeutic strategy against cervical 
cancer. In previous works, we have shown that the extra 
domain A from murine fibronectin (mEDA) can be used to 
target antigens to toll- like receptor 4 (TLR4) expressing 
dendritic cells and induce strong antigen- specific immune 
responses. In the present study, we have produced a 
bivalent therapeutic vaccine candidate consisting of the 
human EDA (hEDA) fused to E7 proteins from HPV16 and 
HPV18 (hEDA- HPVE7-16/18) and evaluate its potential as a 
therapeutic vaccine against cervical cancer.
Materials and methods Recombinant fusion proteins 
containing HPV E7 proteins from HPV16 and HPV18 virus 
subtypes fused to hEDA were produced and tested in vitro 
on their capacity to bind TLR4 and induce the production 
of tumor necrosis factor-α or interleukin (IL)-12 by human 
monocytes and dendritic cells. The immunogenicity and 
potential therapeutic activity of the vaccine in combination 
with cisplatin or with the TLR3 agonist molecules 
polyinosinic‐polycytidylic acid (Poly IC) or Poly ICLC 
was evaluated in mice bearing subcutaneous or genital 
orthotopic HPV16 TC-1 tumors.
results hEDA- HPVE7-16/18 prototype vaccine binds 
human TLR4 and stimulate TLR4- dependent signaling 
pathways and IL-12 production by human monocyte- 
derived dendritic cell. Vaccination with hEDA- HPVE7-16/18 
induced strong HPVE7- specific Cytotoxic T lymphocyte 
(CTL) responses and eliminated established tumors in 
the TC-1- based tumor model. The antitumor efficacy was 
significantly improved by combining the fusion protein with 
cisplatin or with the TLR-3 ligand Poly IC and especially 
with the stabilized analog Poly ICLC. Moreover, hEDA- 
HPVE7-16/18+Poly ICLC induced full tumor regression in 
100% of mice bearing orthotopic genital HPV tumors.
Conclusion Our results suggest that this therapeutic 
vaccine formulation may be an effective treatment for 
cervical tumors that do not respond to current therapies.
IntroduCtIon
Human papillomavirus (HPV) infection is 
the main cause of cervical cancer.1 Among 
the >150 HPV types identified, 12–14 HPV 
types have been categorized as high- risk 
HPV because of their oncogenic activity in 
cervical cancer,2 HPV16 and HPV18 being 
responsible for >70% of all cervical cancer 
cases.3 Prophylactic HPV vaccines are exhib-
iting great promise in reducing the burden 
of this disease.4 However, there is limited 
progress toward the development of immune 
therapeutic strategies for those women 
already infected with HPV who do not benefit 
from the current prophylactic vaccines. It is 
believed that T- cell immune responses, in 
particular against E7 protein, may play an 
important role in resolution of HPV‐induced 
lesions.5 Thus, a vaccination strategy able 
to activate strong E7- specific T- cell immune 
responses might be contemplated as thera-
peutic alternative for cervical carcinoma.
The unique capacity of dendritic cells 
(DC) to take up antigens, generate major 
histocompatibility complex (MHC)- peptide 
complexes and elicit immune responses has 
prompted many laboratories to use DC in 
clinical trials. However, ex vivo manipula-
tion of DC for the production of DC‐based 
vaccines is expensive, time consuming and 
difficult to standardize.6 Therefore, a proce-
dure to target DC with antigens in vivo would 
greatly facilitate vaccination protocols.7–12 
Since maturation of DCs is an essential step 
to trigger adaptive immune responses,13 in 
previous works we chose a toll- like receptor 
4 (TLR4) protein agonist (the extra domain 
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A from fibronectin (EDA)) to simultaneously target the 
antigen to DCs and induce their maturation. Vaccination 
with fusion proteins containing murine EDA (mEDA) 
and a cognate antigen induce strong antigen- specific 
T- cell responses with antiviral, antibacterial or antitumor 
potential.14–17 We found that the fusion protein mEDA- 
HPVE7-16 containing the EDA from murine fibronectin 
targets HPV E7 protein (from HPV16 genotype) to DCs 
and induce strong antitumor CD8+ T- cell responses.15 
In the present study, we have conducted the preclinical 
development for a fusion protein EDA- HPVE7 in order to 
move this vaccine candidate to clinical trials in patients. 
We aim to select a candidate vaccine incorporating the 
human version of EDA (hEDA) fused to E7 proteins 
from HPV16 and HPV18 (hEDA- HPVE7-16/18). We have 
compared various candidates on their relative abilities to 
bind TLR4, stimulate TLR4- dependent signaling path-
ways, induce HPVE7- specific CTL responses and elimi-
nate established tumors in various TC-1- based models. 
Combination of vaccines and chemotherapy or immuno-
logical adjuvants such as the TLR3 agonist Poly IC and 
its stabilized analog Poly ICLC was also evaluated. The 
often poor correlation observed between efficacy in the 
widely used subcutaneous TC-1 tumor model and clinical 
trials against HPV- related malignancies prompted us to 
evaluate the therapeutic efficacy of our vaccine in a more 
realistic and predictive in vivo model for HPV- associated 
genital cancer based on orthotopic implantation of tumor 
cells.18 We found that hEDA- HPVE7-16/18 in combina-
tion with Poly ICLC adjuvant induced E7- specific CD8+ 
T- cell effector responses and achieved a complete thera-
peutic response in this tumor model.
MAterIAls And Methods
Cell lines and mice
TC-1 cells expressing the oncogenes HaRas, HPV16- E6 
and HPV16- E719 were obtained from the American 
Type Culture Collection (LGC Promochem, Molsheim, 
France). Its variant TC-1 P3 (A15) cell line with down-
regulated MHC class I expression20 was kindly provided 
by Dr TC Wu (MD, USA). TC-1 cells expressing lucif-
erase (LC-1 Luc) were then generated by lentiviral 
infection.18 THP-1 human monocyte- derived cells were 
obtained from The American Type Culture Collection, 
Manassas, Virginia, USA). Cells were grown in complete 
medium (CM) consisting of RPMI-1640 supplemented 
with 10% fetal calf serum, 100 U/mL penicillin, 
100 µg/mL streptomycin, 2 mM L- glutamine and 50 µM 
2- mercaptoethanol.
Specific pathogen‐free, female C57BL/6 wild- type mice 
aged 7–10 weeks (Charles River) were used in compli-
ance with the ethical directives of the Swiss and Spanish 
veterinary authorities. They were housed in appropriated 
animal care facilities during the experimental period and 
handled following the international guidelines required 
for experimentation with animals.
Peptides and reagents
Synthetic peptides were purchased from Genecust 
(Dudelange, Luxembourg) and dissolved in 10% dimethyl 
sulfoxide in phosphate- buffered saline (PBS). The purity 
of the peptides was >80%. Montanide was provided by 
SEPPIC and Berna- Biotech (Bern). Polyinosinic‐polycyt-
idylic acid (Poly IC) was purchased from InvivoGen (San 
Diego, California, USA) and was diluted in PBS before 
injection. Poly- ICLC (Hiltonol, a synthetic poly- IC, stabi-
lized with polylysine and carboxymethylcellulose) was 
kindly provided by Dr Andrés Salazar (Oncovir, NW 
Washington, District of Columbia, USA). Lipopolysac-
charide (LPS) from Escherichia coli 055:B5 was purchased 
from Sigma (Madrid, Spain).
The hEDA- HPVE7-16 and hEDA- HPVE7-16/18 were 
produced in E. coli BL21 using a T7 expression vector and 
purified from inclusion bodies by size exclusion chro-
matography (Biotecnol, Oeiras, Portugal). The mEDA- 
HPVE7-16 protein was produced at CIMA as previously 
described.15 The levels of endotoxin were below 0.1 
EU/µg protein as tested by Quantitative Chromogenic 
Limulus Amebocyte Lysate assay (Cambrex, Walkersville, 
Maryland, USA).
sample processing for transmission electron microscopy
For ultrastructural studies by transmission electron 
microscopy, cells from each treatment were adhered to 
poly- L- lysine- coated coverslips and processed as previ-
ously described with minor modifications.21 Ultrathin, 70 
nm thick sections of epoxy resin 812 embedded samples 
were obtained with an Ultracut UCT ultramicrotome 
(Leica Microsystems), transferred to 200 mesh Nickel 
EM grids (Gilder, Lincolnshire, UK) and stained with 3% 
aqueous uranyl acetate (10 min) and lead citrate (2 min) 
(Electron Microscopy Science). Sections were visualized 
on a JEOL JEM 1200 EXII electron microscope operating 
at 100 kV (JEOL, Tokyo, Japan). DC and T cells can be 
distinguished by transmission electron microscopy, due 
to the distinctive features of both cellular types.22 DC are 
larger than T cells, with a less electron- dense nucleus and 
an abundant cytoplasm in which large amount of organ-
elles, specially mitochondria, endoplasmic reticulum, 
endosomes and lysosomes, are distributed throughout 
the cell volume. T cells are smaller and more spherical, 
with a reduced cytoplasm and a highly electron- dense 
nucleus occupying the majority of the cell volume, with 
the organelles accumulated in one area of the cytoplasm.
In vitro analysis of dC activation
Human DCs were generated from monocytes obtained 
from 80 mL of blood. Briefly, peripheral blood mononu-
clear cells (PBMCs) were separated using a Ficoll gradient, 
and CD14+ cells were enriched using CD14 microbeads 
(Miltenyi Biotec, Bergisch Gladbach, Germany). These 
cells were plated in 96- well plates at 106 cells/mL in 
culture medium supplemented with GM- CSF (Peprotech, 
London, UK; 1000 U/mL), and interleukin (IL)-4 (Pepro-
tech; 1000 U/mL). They were subsequently cultured for 5 
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days (37°C, 5% CO2), with fresh medium containing cyto-
kines added on day 4.
At day 5, cells were cultured in the presence of various 
concentrations of EDA proteins (2, 1, 0.1 and 0.01 µM), 
0.1 µg/mL LPS or culture medium. After 48 hours, super-
natants were harvested and IL-12 (p70) was measured 
by ELISA according to the manufacturer’s instructions 
(BD- Pharmingen, San Jose, California, USA).
In vitro analysis of monocyte/macrophage activation
THP-1 cells were plated at 0.2×106 cells/well in 96- well 
plates using CM and then cultured with different concen-
trations of the EDA proteins, 0.1 µg/mL of LPS, or left 
untreated for 15 hours. TNF-α release was then quanti-
fied in the culture medium using a commercial ELISA 
assay (BD- Pharmingen) according to manufacturer’s 
instructions.
binding assays to tlr4 expressing cells
To test whether the recombinant proteins were able 
to bind to TLR4 expressing cells, we used HEK293 
expressing human TLR4- MD2- CD14 (HEK TLR4; Invi-
vogen) or LacZ (HEK LacZ; InvivoGen) as a negative 
control. Cells were pulsed with 0.5 µM of the Alexa Fluor 
488- labeled proteins (Alexa Fluor 488 Microscale Protein 
Labeling Kit; Invitrogen, Paisley, Scotland) for 1 hour at 
4°C, washed with PBS and analyzed by flow cytometry.
Immunization experiments and measurement of immune 
responses
For interferon (IFN)-γ ELISPOT assays, mice were immu-
nized as described in the ‘Results’ section. When indi-
cated, mice received two immunizations at days 1 and 8. 
In some experiments, vaccination with the recombinant 
proteins was combined with intraperitoneal administra-
tion of cisplatin at days 5 and 8 (5 mg/kg body weight). 
PBMCs were prepared from tail- blood and purified on 
lympholyte M (Cedarlane CL 5035) gradients. Tissues 
(spleen and cervix- vagina (CV)) were harvested after 
sacrifice and single- cell suspensions were obtained as 
previously described.23 24
IFN-γ ELISPOT assays were performed as previ-
ously described23 using Multiscreen- HA 96- well plates 
(MAHA S4510, Millipore; Darmstadt, Germany), anti- 
IFN-γ monoclonal antibody (R4- 6A2, Becton Dickinson 
Pharmingen; Allschwil, Switzerland), biotinylated anti- 
IFN-γ monoclonal antibody (XMG1.2, Becton Dickinson 
Pharmingen) and streptavidin- AP (Roche). One or four 
hundred thousand cells/well were incubated in dupli-
cate with 1 µg/mL of H- 2Db restricted E749–57 peptide or 
medium alone (control wells). For CV cells, 3×104 bone 
marrow- derived dendritic cells/well were used as antigen- 
presenting cells and incubated for 1 hour with E749–57 
peptide or medium alone, prior to addition of 1×105 CV 
cells. Following 16–24 hours, E7- specific responses were 
defined as the number of IFN-γ spots/105 cells in the 
E7- stimulated wells minus the number of IFN-γ spots/105 
cells in the control wells (<3 spots/well).
Tetramer and T- cell labeling was performed as previously 
described,25 using phycoerythrin (PE)- conjugated E749–57 
and L1165–173 (as a control), H- 2Db- restricted tetramers 
(TetE7 and TetL1, respectively; TCMetrix; Epalinges, 
Switzerland) and allophycocyanine (APC)- labeled CD8α 
(clone 53–6.7). The proportion of TetE7+ CD8+ T cells 
among total cells was calculated after subtraction of the 
background, which was measured using control TetL1 
(<20 events/CV). Cell acquisition and analysis were 
performed using a Gallios Flow Cytometer (Beckman 
Coulter) and FlowJo Software (Tree Star).
tumor treatment
TC-1-based subcutaneous tumor models
TC-1, TC-1 Luc or TC-1 P3 (A15) cells (1×105, 3×105 or 
1×105 cells/mouse, respectively) were injected into the 
shaved back (left side) of C57BL/6 mice in 200 µL of 
PBS. At days 7 (when the tumors reached 5 mm in diam-
eter) and 14, the mice were treated subcutaneously in the 
back (right side) with the indicated immunogens and/
or adjuvants in the same mixture. In addition, as a posi-
tive control of tumor growth, mice were challenged with 
tumor cells and later treated with PBS only. Tumor size 
(presented as the average of two perpendicular diameters 
(mm)) was measured at regular intervals. Mice were sacri-
ficed when the mean tumor diameter was >18 mm.
Orthotopic tumor model
To induce genital tumors, anesthetized diestrus synchro-
nized mice pretreated with 4% nonoxynol-9 (N9, Igepal; 
Sigma) were challenged intravaginally with 12,500–
20,000 TC-1- luc cells at day 1.18 Genital tumor growth was 
monitored by bioluminescence using a Xenogen imaging 
system (Xenogen/Caliper Life Science, kindly provided 
by CIF, UNIL, Lausanne) as previously described.18 
Vaccination was initiated 8 days after genital tumor 
implantation.
statistical analyses
Immune responses were analyzed using non- parametric 
and unpaired T tests. P values <0.05 were considered to 
be statistically significant. Kaplan–Meier plots were used 
to assess survival, and differences were analyzed using the 
log- rank test (GraphPad Prism; GraphPad Software, Cali-
fornia, USA).
results
linkage to edA improves t-dC synapse dimensions
Fusion of an antigen to mEDA favors antigen uptake by 
TLR4 expressing DC and improves its presentation to 
antigen- specific T cells.14 To get further insight on this 
improvement of antigen presentation, we studied the 
synaptic structure with a better spatial resolution by exam-
ining T- DC synapses by electron microscopy. Thus, DCs 
were incubated with equimolar amounts of SIINFEKL 
peptide, ovalbumin (OVA) or the fusion proteins EDA- 
SIINFEKL and EDA- OVA. As a negative control, DCs were 
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Figure 1 Linkage of ovalbumin (OVA) antigens to extra domain A (EDA) improves immunological synapse. Dendritic cell 
(DC) incubated with equimolar amounts of SIINFEKL, EDA- SIINFEKL, EDA- OVA, OVA or left untreated, were co- cultured with 
purified CD8+ T cell from OT- I mice. Then cells were fixed, resin embedded and thin sectioned to be visualized by electron 
microscopy. (A) Representative micrographs from each group (upper row) and details of contacting areas or synapses (lower 
row). Magnification bars in upper row correspond to 0.5 µm, and in lower row correspond to 200 nm. (B) Analyzes of longest 
close apposition (nm), the fraction of the synapses showing one close apposition >400 nm and the mean size of continuous 
region of close apposition corresponding to 10–12 conjugates/group, measured in electron micrographs from thin sections of 
cells. Results are representative of two independent experiments. *P<0.05, **p<0.01.
maintained with culture medium alone. After an over-
night incubation, CD8+ T cells from OT-1 transgenic mice 
were added to the DC cultures and incubated for 30 min, 
fixed and analyzed by electron microscopy as described 
in ‘Materials and methods’ section. In figure 1A, repre-
sentative micrographs from each group (upper row) and 
details of contacting areas or synapses (lower row) are 
included. It was found that length of close appositions, 
the fraction of the immunological synapse (IS) or the size 
of the IS regions of close apposition were significantly 
increased when DC were pre- incubated with the antigen. 
SIINFEKL peptide, which does not require antigen 
internalization or intracellular processing, induced 
close apposition between T cells and DC. On the other 
hand, OVA protein, which requires antigen processing, 
was significantly less efficient in the promotion of close 
appositions. However, both EDA- SIINFEKL and EDA- 
OVA, significantly improved DC- T- cell interactions indi-
cating that antigen presentation to OT- T cells was clearly 
favored (figure 1B). This enhancement in DC- T- cell close 
appositions correlates with an improvement in T- cell 
activation (T- cell proliferation and IFN-γ production) 
reported in previous works14–16 and indicates that EDA 
fusion to antigen proteins induces DC activation and 
favors antigen presentation to T cells.
therapeutic efficacy of medA-hPVe7-16 alone in tC-1 tumor 
models
Immunization of mice with mEDA- HPVE7-16 fusion 
protein induced antitumor CD8+ T- cell responses and 
protected mice from tumor challenge with TC-1 cells.15 
In line with these previous results, we found that intra-
tumor administration of five doses of mEDA- HPVE7-16 
fusion protein (3 nmol at days 3, 4, 5, 6 and 7 after tumor 
challenge) induced tumor rejection in 50% of animals. 
The antitumor efficacy was higher when mice were chal-
lenged with TC-1 cells expressing the reporter gene lucif-
erase (TC-1 Luc), despite the animals received three times 
more tumor cells (3×105 cells per mice), suggesting that 
these cells are more immunogenic because the ectopic 
expression of the reporter gene. However, the antitumor 
efficacy was reduced importantly in mice challenged 
with TC-1 P3 (A15) with downregulated MHC class I 
expression, a common feature associated with most HPV- 
associated cervical cancers.20 Indeed, therapeutic efficacy 
was reduced from 50% for TC-1 or 77% for TC-1 Luc to 
25% for TC-1 P3 (A15) (figure 2).
therapeutic efficacy of medA-hPVe7-16 in combination with 
Poly IC adjuvant
Once observed that the antitumor effect of the mEDA- 
HPVE7-16 vaccine alone was limited in the tumor model 
with low MHC expression, we evaluated the beneficial 
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Figure 2 Therapeutic efficacy of intratumor mEDA- HPVE7-16 immunotherapy in the absence of adjuvants in different TC-1- 
based tumor models. C57BL/6 mice were challenged subcutaneously with 1×105 TC-1, 3×105 TC-1 Luc or 1×105 TC-1 P3 (A15) 
tumor cells and treated as indicated (n=8 per group). mEDA- HPVE7-16 protein was administered intratumorally (i.t.) at days 3, 
4, 5, 6 and 7 (3 nmols/mouse/day) (n=8–9 per group). Tumor size (average of two perpendicular diameters (mm)) was measured 
at regular intervals. The ratio of tumor- free mice/total mice is shown at day 90 for each treatment. Mice were sacrificed when 
tumor diameters reached 18 mm or when warranted based on the health of the animals. Results are representative of three 
independent experiments. PBS, phosphate- buffered saline.
effect of its combination with an adjuvant in the more 
difficult- to- treat TC-1 P3 (A15) tumor model. Thus, 
C57BL/6 mice were injected subcutaneously with 105 
TC-1 P3 (A15) cells and 7 days later, when tumor mean 
diameters were around 5 mm, they were treated intratu-
morally with PBS; 50 µg of Poly IC; 3 nmol of EDA- HPVE7 
or 3 nmol EDA- HPVE7+50 µg of Poly IC in the same 
mixture. A group of mice was treated subcutaneously with 
3 nmol EDA- HPVE7+50 µg of Poly IC. A second immuniza-
tion was done at day 14 following the same immunization 
protocol for each group. Tumors from mice treated with 
PBS or with Poly IC alone grew progressively and mice had 
to be sacrificed between days 20 and 35 (figure 3). The 
protein mEDA- HPVE7-16 alone, in the absence of adju-
vant, achieved tumor eradication in only two out of eight 
animals (25%), whereas treatment with the combina-
tion of mEDA- HPVE7-16 and Poly IC achieved complete 
tumor eradication in three out of eight (37.5 %) when 
the vaccine was injected subcutaneously and in five out 
of eight (62.5%) when the vaccine was injected intratu-
morally (figure 3) (p=0.0004 and p=0.04 as determined 
by likelihood ratio test between mice treated with EDA- 
HPVE7 intratumorally. or subcutaneously with respect to 
intratumorally EDA- HPVE7 alone, and p<0.0005 as deter-
mined by log- rank test when comparing survival curves).
therapeutic efficacy of medA-hPVe7-16 in combination with 
Poly IClC adjuvant
We substituted Poly IC by the stabilized Poly ICLC adju-
vant (Hiltonol, Oncovir), which has proved to be 5- fold 
to 10- fold more resistant to hydrolysis and induced signif-
icant serum levels of IFN-γ.26 27 As controls, we included 
the synthetic peptide E743–77, containing the E749–57 
H2- Db- restricted CTL epitope with its natural flanking 
sequences28 and that has been proven to have therapeutic 
efficacy when combined with adjuvants.29–31 Thus, we 
included Poly ICLC as an adjuvant for mEDA- HPVE7-16 
when it is administered subcutaneously, which represents 
a more feasible delivery route for use in patients. TC-1 
P3 (A15) tumor- bearing C57BL/6 mice were treated by 
subcutaneous injection with: PBS; Poly IC; Poly ICLC; 
mEDA- HPVE7-16 alone; mEDA- HPVE7-16+Poly IC; 
100 µg of peptide E743–77 alone; 100 µg of peptide E743–
77+Poly ICLC or mEDA- HPVE7-16+Poly ICLC following 
the same schedule as in the previous experiment. No 
therapeutic effect was observed in mice treated with PBS, 
Poly IC, Poly ICLC or with peptide E743–77 alone, whereas 
mEDA- HPVE7-16 alone or the combination of E743–77 
peptide+Poly ICLC induced tumor rejection in 12.5%. 
In agreement with results found in figure 3, combination 
of mEDA- HPVE7-16+Poly IC cured tumors in 75% of the 
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Figure 3 Therapeutic efficacy of mEDA- HPVE7-16 immunotherapy alone or in combination with polyinosinic‐polycytidylic acid 
(Poly IC) adjuvant in TC-1 P3 (A15)- based tumor model. C57BL/6 mice were challenged subcutaneously (s.c.) with 1×105 TC-1 
P3 (A15) tumor cells. Seven days later, when the tumor diameter is above 5 mm, they were treated as indicated (n=8 per group). 
They were subsequently boosted at day 14. Mice were treated with mEDA- HPVE7-16 protein (3 nmols/mouse)+Poly IC (50 µg/
mouse) intratumorally (i.t.) or s.c. Tumor size (average of two perpendicular diameters (mm)) was measured at regular intervals. 
The ratio of tumor- free mice/total mice is shown at day 90 for each treatment. Mice were sacrificed when tumor diameters 
reached 18 mm or when warranted based on the health of the animals. Kaplan- Meier plot is depicted for each treatment. 
Results are representative of two independent experiments. PBS, phosphate- buffered saline.
animals. Nevertheless, combination of mEDA- HPVE7-
16+Poly ICLC induced tumor rejection in 100% of the 
animals (figure 4A,B).
therapeutic efficacy of medA-hPVe7-16 in combination with 
cisplatin
Cisplatin- based chemotherapy has been the standard of 
care for metastatic cervical cancer for decades. Cisplatin 
treatment could have a negative impact on immune cells 
stimulated by the vaccine and could reduce its thera-
peutic efficacy. In a previous report, Small et al32 found 
that, although cisplatin administration did not prevent 
the induction of an effective immune response after 
vaccination, intraperitoneal administration of three doses 
of 5 mg/kg cisplatin had an effect reducing the number 
of peptide- specific IFN-γ-producing cells. We carried out a 
previous experiment to evaluate the effect of cisplatin on 
the immunogenicity of mEDA- HPVE7-16. Thus, mice were 
immunized subcutaneously with 3 nmol mEDA- HPVE7-16 
and treated intraperitoneally with 5 mg/kg cisplatin or 
with saline at days 0 and 3. Seven days after immunization, 
we evaluated the number of specific IFN-γ-producing cells 
in response to stimulation with peptide E749–57 or with 
irradiated TC-1 tumor cells. Although it was observed a 
slight increase on the immune response in mice treated 
with cisplatin this difference did not reach statistical 
significance (online supplementary figure 1). Therefore, 
we assessed whether cisplatin (5 mg/kg body weight at 
days 5 and 8) might represent a useful adjunct therapy 
for use with mEDA- HPVE7-16 immunotherapy following 
challenge with TC-1 P3 (A15) tumor cells. As described 
in figure 5, intratumoral treatment with mEDA- HPVE7-16 
alone was able to cure 37.5% of tumors, whereas the addi-
tion of cisplatin to the treatment regimen led to the erad-
ication of tumors in 75% of mice (p=0.0711). In contrast, 
cisplatin alone was comparable to PBS and appeared to 
have little effect on tumor growth. Notably, treatment 
of mice with intratumoral E743–77 peptide and cisplatin 
yielded a cure rate of 25%, significantly inferior effect 
than mEDA- HPVE7-16+cisplatin (25% vs 75%, p=0.0127) 
(figure 5A). Chemotherapy also improved the antitumor 
effect of mEDA- HPVE7-16 when the vaccine was admin-
istered by the subcutaneous route (final cure rate of 
37.5% vs 0% with the vaccine alone, p<0.05, figure 5B). 
Thus, although subcutaneous administration of mEDA- 
HPVE7-16 appeared to be less efficacious when compared 
with intratumoral vaccination, combination with cisplatin 
improved the therapeutic responses in both cases.
therapeutic efficacy of a fusion protein between hedA and 
hPVe7 proteins from hPV16 and hPV18 genotypes
To advance the preclinical development of the mEDA- 
HPVE7-16 vaccine toward clinical application in patients 
with HPV- related malignancies, we generated hEDA- 
HPVE7-16, which contains the hEDA and lacks the histi-
dine tag included in mEDA- HPVE7-16. In parallel, we 
attempted to improve our vaccine candidate adding the 
E7 protein from HPV18 to broaden the target popula-
tion (bivalent vaccine) (figure 6A). We have produced 
(figure 6B) and tested the immunogenicity and antitumor 
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Figure 4 Therapeutic efficacy of mEDA- HPVE7-16 immunotherapy alone or in combination with Poly ICLC adjuvant in TC-1 
P3 (A15)- based tumor model. C57BL/6 mice were injected subcutaneously (s.c.) with 1×105 TC-1 P3 (A15) cells. At days 7 (5 
mm tumor diameter) and 14, mice were treated s.c. with the indicated immunogens. Proteins were administered at a dose of 3 
nmols/mouse, whereas Poly ICLC, Poly IC and E743–77 peptide were delivered at 100 µg per mouse. (A) Tumor size (the average 
of two perpendicular diameters (mm)) was measured at regular intervals. The ratio of tumor- free mice/total number of mice 
treated is shown at day 90 for each treatment. (B) Survival following treatment is depicted using a Kaplan- Meier plot. Mice 
were sacrificed when tumor diameters reached 18 mm. Results are representative of three independent experiments. ns, not 
significant; PBS, phosphate- buffered saline.
efficacy of hEDA- HPVE7 vaccine candidates (hEDA- 
HPVE7-16 and hEDA- HPVE7-16/18) and compared with 
results obtained with the mEDA- HPVE7-16 prototype 
vaccine (mEDA- HPVE7-16).
We first studied whether the new vaccine candidates 
maintained TLR4- binding capacity using HEK 293 cells 
stably transfected with human TRL4 (293- TLR4). It 
was found that mEDA- HPVE7-16 and hEDA- HPVE7-
16/18- labeled with Alexa Fluor 488 displayed high and 
comparable TLR4- binding capacities (40.2% and 36.9%, 
respectively) (figure 6C). Surprisingly, hEDA- HPVE7-
16- Alexa displayed a much lower level of fluorescence 
(19.5%) indicating a more limited capacity to bind TLR4.
We next tested the ability of the different EDA- 
HPVE7 proteins to induce the production of TNF-α by 
TLR4- expressing cell line THP-1 (human monocytes) 
and the IL-12 production by human monocyte- derived 
DCs. mEDA- HPVE7-16, hEDA- HPVE7-16 and hEDA- 
HPVE7-16-18 candidates induced production of high 
levels of TNF-α in a dose- dependent manner (figure 6D). 
We also observed that, while mEDA- HPVE7-16 induced 
low levels of IL-12, hEDA- HPVE7-16/18 and, to a lower 
extent, hEDA- HPVE7-16, were capable of inducing 
high levels of IL-12 production by human- derived DC 
(figure 6E).
In order to compare the relative ability of the EDA- 
HPVE7 fusion proteins to induce HPVE7- specific T- cell 
responses in vivo, C57BL/6 mice were immunized subcu-
taneously with 3 nmol of each of the vaccine candidates in 
the presence or absence of Poly IC. Also, the hEDA protein 
alone and the E743–77 peptide were used as controls. Ten 
days later, mice were sacrificed and their spleen cells were 
cultured in the presence or absence of E749–57 peptide. 
Subsequently, the number of IFN-γ-producing cells was 
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Figure 5 Therapeutic efficacy of subcutaneous (s.c.) mEDA- HPVE7-16 immunotherapy combined with cisplatin chemotherapy. 
C57BL/6 mice were challenged s.c. with 1×105 TC-1 P3 (A15) tumor cells and treated as indicated (n=8 per group). mEDA- 
HPVE7-16 (3 nmol), mEDA (3 nmol), Poly IC (50 µg/mouse) and peptide E743–77 (20 µg/mouse) were s.c. administered at days 
5, 8 and 11, whereas cisplatin (5 mg/kg body weight) was administered intraperitoneally (i.p.) at days 5 and 8. (A) Tumor size 
(average of two perpendicular diameters (mm)) was measured at regular intervals. The ratio of tumor- free mice/total mice is 
shown at day 90 for each treatment. (B) A Kaplan- Meier plot is depicted for each treatment. Mice were sacrificed when tumor 
diameters reached 18 mm or based on the health of the individual animals. PBS, phosphate- buffered saline.
measured by ELISPOT. Mice that did not receive Poly IC 
had low numbers of E749–57- specific IFN-γ-producing cells 
in comparison to mice treated with Poly IC (figure 6F). 
Vaccination with E743–77 alone or plus Poly IC did not yield 
an E749–57- specific IFN-γ response, further supporting 
the immunostimulatory capacity of EDA. In contrast, 
hEDA- HPVE7-16/18 combined with Poly IC induced 
strong CTL responses against the E749–57 peptide, with 
similar efficacy to that of the mEDA- HPVE7-16 prototype 
vaccine. Once demonstrated similar immunogenicity 
between mEDA- HPVE7-16 and hEDA- HPVE7-16/18, we 
conducted the same assay in the presence of the stabi-
lized version Poly ICLC, and tested the immune response 
against CD8+ T- cell epitopes from HPV16 and HPV 18 
genotypes. Overall, combination of mEDA- HPVE7-16 
and hEDA- HPVE7-16/18 proteins with Poly ICLC led to 
a similar E749–57- specific immune response as with Poly IC. 
However, an increased number of IFN-γ-producing cells 
were seen when using Poly ICLC (figure 6G). Impor-
tantly, vaccination with hEDA- HPVE7-16/18 was able to 
induce immune responses specific for both HPV16 and 
HPV18 genotypes (figure 6G). Indeed, mice immunized 
with hEDA- HPVE7-16/18 elicited IFN-γ-producing cells 
specific for HPV18 E77–15 and E786-94 epitopes, not elicited 
by mEDA- HPVE7-16.
We then evaluated the therapeutic efficacy of hEDA- 
HPVE7-16/18 vaccine candidate in the TC-1 P3 (A15) 
tumor model. C57BL/6 mice were injected subcutane-
ously with 1×105 TC-1 P3 (A15) cells and at days 7 and 
14 were treated subcutaneously with 3 nmol of hEDA- 
HPVE7-16/18+50 µg of Poly ICLC or with PBS. We 
found that tumors were eradicated in 100% of animals 
after vaccination with hEDA- HPVE7-16/18+Poly ICLC 
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Figure 6 In vivo induction of cellular immune responses against HPVE7 following immunization with EDA- HPVE7 vaccine 
candidates. (A) Schematic representation of the candidate fusion proteins. (B) Coomassie staining of the produced proteins 
(lane 1: mEDA- HPVE7-16; lane 2: molecular weight marker; lane 3: hEDA- HPVE7-16; lane 4: hEDA- HPVE7-16/18). (C) Binding 
of the fusion proteins to 293- toll- like receptor 4 (TLR4) and 293- LacZ expressing cells, measured by flow cytometry. (D) Tumor 
necrosis factor (TNF)-α production by THP-1 cells in response to stimulation with the indicated proteins. (E) Interleukin (IL)-12 
production by human monocyte- derived dendritic cell (DC) in response to protein stimulation. (F) Number of interferon (IFN)-
γ-producing cells specific for peptide E749–57 peptide in C57BL/6 mice previously immunized with the indicated protein±Poly IC. 
(G) Number of IFN-γ-producing cells specific for peptides from HPV16 and HPV18 genotypes in C57BL/6 mice previously 
immunized with hEDA- HPVE7-16/18 protein+Poly ICLC. (H) Antitumor efficacy of subcutaneous immunization with PBS, 
hEDA- HPVE7-16/18 alone or hEDA- HPVE7-16/18+Poly ICLC in C57BL/6 mice bearing TC-1 P3 (A15) tumors. Tumor size was 
measured at regular intervals. The ratio of tumor- free mice/total number of mice treated is shown at day 90 for each treatment. 
Survival following treatment is depicted using a Kaplan- Meier plot. Results are representative of two independent experiments. 
n.s., not significant; PBS, phosphate- buffered saline.
(figure 6H). Treatment of mice with hEDA- HPVE7-16/18 
in combination with cisplatin was also able to cure five out 
of eight (62.5%) animals (online supplementary figure 
2). These results suggest that the newly developed biva-
lent vaccine hEDA- HPVE7-16/18 could generate clinical 
benefit in patients with cervical cancer in combination 
with the currently applied treatments regimens when 
administered with Poly ICLC. In a next step, we evalu-
ated the therapeutic efficacy of hEDA- HPVE7-16/18+Poly 
ICLC combination in an orthotopic genital tumor model.
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evaluation of edA-hPVe7 vaccine in a murine orthotopic 
genital cancer model
The therapeutic efficacy of these vaccines was also tested 
in an orthotopic tumor model which represents a more 
realistic and predictive model for evaluation of cervical 
cancer immunotherapies.24 In this model, luciferase- 
expressing TC-1 cells are directly instilled in the vagina, 
resulting in tumors that require the homing of vaccine- 
induced immune responses to the genital mucosa. 
Genital tumors were established in the mice as described 
in methods section and monitored by in vivo biolumi-
nescence over time. We then evaluated the capacity of 
the hEDA- HPVE7-16/18 vaccine to induce antitumor 
effector E7- specific CD8+ T- cell responses, compared 
with an antigen formulation based on 13 synthetic long 
peptides (SLP) (table 1) emulsified in IFA/Montanide. 
This peptide- combined formulation is similar to that used 
in the ISA peptide- based vaccine (ISA SLP), which has 
demonstrated convincing therapeutic effects.33 34 We also 
added a control group consisting of the synthetic peptides 
E71–35 and E743–77+Poly ICLC which includes the sequence 
of the SLP E743–77, already demonstrated to eradicate 
established HPV16 expressing tumors.31 35 Thus, group of 
mice bearing genital tumors were immunized subcutane-
ously at day 1 and day 8 with (i) hEDA- HPVE7-16/18 (3 
nmols)+Poly ICLC (50 µg), (ii) with peptides E71–35 and 
E743–77 (50 µg×2)+Poly ICLC (50 µg) or (iii) with 13 SLP 
peptides (13×50 µg)+IFA/Montanide.
Vaccine- specific immune reactions were evaluated by 
bleeding the mice 7 days after the first and 6 days after the 
second vaccination (postboost) and performing ELISPOT 
assays on the purified PBMCs. E7- specific IFN-γ-secreting 
CD8+ T cells could be detected in the PBMC of the 
majority of the treated mice after the first vaccination 
(figure 7A). Following boosting, a significant improve-
ment of immune reaction was observed in mice vacci-
nated with hEDA- HPVE7-16/18+Poly ICLC (185±50). In 
addition, the response in the E71–35 and E743–77+Poly ICLC 
group was augmented by boosting (94±20). In contrast, 
boosting vaccination with the 13 SLP peptides+Monta-
nide did not have a strong effect (29±8). As expected, 
unvaccinated mice harboring day 21 tumors exhibited a 
relatively small, but detectable, immune response (5±3). 
But more importantly, hEDA- HPVE7-16/18+Poly ICLC 
induced full regression of 100% of the orthotopic tumors 
and was more efficacious than the 13 SLP peptides+Mon-
tanide (p<0.01) or than E71–35 and E743–77+Poly ICLC 
(p=0.067) (figure 7B,C).
dIsCussIon
Vaccination strategies based on the in vivo targeting of 
antigens to DCs have demonstrated to induce specific 
T- cell immunity against tumors and infectious agents.36 
As part of the preclinical development of an EDA- HPVE7- 
based therapeutic vaccine against HPV- related cervical 
carcinoma, we have worked to adapt the mEDA- HPVE7-16 
fusion protein, which was used in initial efficacy experi-
ments in mice, for use in human clinical studies.
We have confirmed the antitumor efficacy of mEDA- 
HPVE7-16 vaccine in the absence of adjuvants eliciting 
a robust cellular immune response. However, the anti-
tumoral efficacy is significantly reduced when the TC-1 
P3 (A15) variant system, with a reported downregulation 
of MHC expression, was used. Therefore, we evaluated 
possible adjunct therapies that might improve the effi-
cacy of mEDA- HPVE7-16 therapeutic HPV vaccine.
Cisplatin- based chemotherapy has been the standard 
of care for metastatic cervical cancer for decades. It is a 
platinum- containing anticancer drug, which binds to and 
crosslinks DNA, ultimately triggering cell death (apop-
tosis).37 Unfortunately, only approximately one- third of 
patients with cervical cancer respond to cisplatin- based 
chemotherapy, with responses typically lasting fewer 
than 12 months.38 It has been suggested that cisplatin 
treatment can promote the release of pro- inflammatory 
substances from dying tumor cells39 40 and convert the 
tumor microenvironment into a more permissive site 
with regard to adaptive immune responses.41 Thus, 
cisplatin co- administration might provide a mechanism 
to augment responses against tumor antigens during 
vaccination.35 42 43 However, it has also been reported that 
cisplatin fails to induce immunogenic tumor cell death 
that would allow to stimulate an anticancer immune 
response.44 In our experiments, the therapeutic efficacy 
of mEDA- HPVE7-16 was significantly improved when it 
was combined with cisplatin. In this regard, intratumor 
administration of EDA- HPVE7 in combination with 
cisplatin (intraperitoneal) was found to be more effica-
cious than subcutaneous administration in the TC-1 P3 
(A15) tumor model. It could be speculated that reduced 
capacity of cisplatin to induce immunogenic cell death 
could be restored by intratumoral administration of 
EDA that might provide a pro- inflammatory signal to DC 
and improve their maturation in situ. Nevertheless, also 
subcutaneous vaccination in combination with cisplatin 
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Figure 7 Evaluation of hEDA- HPVE7-16/18 vaccine in a murine orthotopic genital cancer model. Immune responses to the 
vaccines in naïve mice (A, B) and in mice bearing cervical tumors (C). (A) C57BL/6 mice were immunized by the subcutaneous 
route with the indicated immunogen and 7 days later, E749–57- specific interferon (IFN)-γ-secreting T cells in the indicated organs 
measured by ELISPOT (n=3–4 mice per group). (B) Percentage of E749–57- specific T cells on total CD8
+ T cells was measured 
by tetramer staining (n=3–6 mice per group). (C) Mice received intravaginally TC-1- luc cells at day 1 and were vaccinated at 
days 9 and 16. E7- specific IFN-γ-secreting cells were measured in the peripheral blood mononuclear cells (PBMCs) 7 days after 
the first and 6 days after the second vaccination (n=5 mice per group). (D) Tumor follow- up. Change in tumor bioluminescence 
over time is displayed for each mouse until their sacrifice (data shown by vaccination group). (E) Survival curves. Survival of 
the different vaccinated groups. Survival of mice vaccinated with hEDA- HPVE7-16/18 was higher than survival of mice treated 
with SLP ISA/Montanide or E7 1–32+E7 43-77+Poly ICLC (p<0.0001 and p=0.067, respectively using log- rank test). The initial 
number of mice (gray) and the number of mice surviving at day 68 (black) are also shown. Significant differences were detected 
using the Fisher’s exact test: *p<0.05, ***p<0.001. SLP, synthetic long peptides.
was able to eliminate tumors efficiently in the TC-1 P3 
(A15) model, suggesting that our candidate vaccine 
could generate clinical benefit in combination with the 
currently applied chemotherapy.
We then explored whether the combination of mEDA‐
HPVE7-16 with an adjuvant such as the TLR3 ligand 
poly- IC could improve CTL priming against E7. In this 
TC-1 P3 (A15) tumor model, the use of Poly IC, and 
specially its stabilized version Poly ICLC (Hiltonol) as 
an adjuvant, significantly improved the antitumor effi-
cacy of the vaccine, achieving 100% of tumor rejection. 
These results prompted us to continue our studies with 
theTLR3 ligand poly- ICLC.
As part of the preclinical development of an EDA- 
HPVE7- based vaccine, we adapted mEDA- HPVE7-16 for its 
use in humans. Thus, mEDA was substituted by hEDA and 
the E7 from HPV18 was also incorporated to generate the 
fusion protein hEDA- HPVE7-16/18 to display a broader 
target population (20% increase), which mirrors the 
approach used by existing prophylactic vaccines against 
HPV. Our in vitro experiments confirmed the TLR4- 
binding capacity of hEDA- HPVE7-16/18 vaccine candi-
date. The in vitro findings correlated with the in vivo 
experiments, which measured the induction of HPVE7- 
specific CTL immune responses and therapeutic efficacy 
in the TC-1 P3 (A15) tumor model. In this regard, hEDA- 
HPVE7-16/18 was shown to reproduce the immunostim-
ulatory properties of mEDA- HPVE7-16. But importantly, 
hEDA- HPVE7-16/18 was able to induce specific T- cell 
responses against epitopes from the HPVE7 18 variant, 
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confirming the broader spectrum of the newly developed 
bivalent vaccine.
HPV genotype distribution analyzes in patients with 
invasive cervical cancer indicate that HPV 16 and 
HPV 18 are the two most common types worldwide, 
which together are responsible for >70% of all cervical 
cancers.3 45 Notably, HPV 18- related cervical carcinomas, 
particularly those diagnosed at an early stage, have been 
associated with a poor prognosis and a higher risk of 
relapse,46 47 stressing the need to develop a therapeutic 
vaccine for both HPV16 and HPV18 genotypes. Taken 
together, incorporation of the HPV18 E7 sequence into 
hEDA- HPVE7-16 produced a vaccine candidate that 
yielded high immunogenicity (hEDA- HPVE7-16/18), 
especially when combined with Poly ICLC.
We compared the hEDA- HPVE7-16/18 vaccine candi-
date (hEDA- HPVE7-16/18+Poly ICLC) with a previously 
developed vaccine in an orthotopic model of cervical 
carcinoma. Immune response induced with the 13 SLP 
peptides+Montanide in healthy mice was almost undetect-
able in spleen, PBMC or in the cervical mucosa. However, 
subcutaneous immunization with hEDA- HPVE7-16/18 
or E7 1–35 and E7 43–77 (both adjuvanted with Poly ICLC) 
induced clear E7- specific immune responses in the spleen 
and PBMCs (online supplementary figure 3). Interestingly, 
E7- specific immune responses induced by the vaccines 
were higher in mice bearing genital tumors, the hEDA- 
HPVE7-16/18 vaccine being the more immunogenic after 
boosting when compared with unvaccinated mice. These 
results might suggest that the presence of genital tumors 
contributed somehow to the observed immune responses 
(in PBMCs) following hEDA- HPVE7-16/18 vaccina-
tion. Notably, the high E7- specific CD8+ T- cell responses 
observed in PBMCs from hEDA- HPVE7-16/18 vaccinated 
mice were associated with regression of genital tumors. 
As a result, the hEDA- HPVE7-16/18 vaccine produced a 
100% survival rate. Tumor rejection in this unique immu-
nocompetent animal model of genital HPV‐expressing 
tumors, which retains several immunological features of 
naturally occurring HPV tumors,18 requires that vaccine‐
induced immune responses traffic to the GM and over-
come local immunosuppression to allow tumor control. 
Future experiments are needed to verify the traffic of 
antitumor T cells induced by the vaccine to the genital 
mucosa and overcome local immunosuppression to allow 
tumor control. This is probably similar to what is neces-
sary to induce regression of HPV lesions in patients, and 
thus these results may better predict the therapeutic effi-
cacy of our candidate vaccination in patients harboring 
high‐grade genital lesions.
In summary, we have generated a bivalent HPV vaccine 
based on a fusion protein between hEDA and the E7 
proteins from HPV16 and HPV18 genotypes. This fusion 
protein hEDA- HPVE7-16/18 retains the TLR4- binding 
capacity and pro- inflamatory activities of mEDA and 
induced strong anti- E7 immune responses in vivo. Vacci-
nation with hEDA- HPVE7-16/18 combined with cisplatin 
or with Poly ICLC have a strong therapeutic potential 
in relevant murine models of cervical carcinoma. Our 
results suggest that this therapeutic vaccine approach is 
promising for the treatment of cervical tumors that do 
not respond to current immunotherapies.
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